|Bid||54.04 x 1800|
|Ask||54.31 x 800|
|Day's Range||52.68 - 55.06|
|52 Week Range||11.55 - 56.17|
|Beta (5Y Monthly)||3.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 03, 2021 - Nov. 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.25|
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. The Company intends to utilize the subcutaneous formulation of CDX-0159 in its Phase 2 program in chronic urt